NEW YORK (GenomeWeb) – Transgenomic and privately held Precipio Diagnostics said today that they have entered into a merger agreement that will make Precipio a wholly owned subsidiary of Transgenomic, with Transgenomic adopting the name Precipio, Inc.

The merger, expected to close in 2016, is pending approval by Transgenomic shareholders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.